|
|
|
|
 |
NEWS |
ARTICLES
Hormone Replacement Therapy, Prempro and Sex Drive
(06/09/2004,
WebMD Health)
"A new study may help explain why so many women taking
hormones for birth control or menopause complain of
losing their sex drive."
"Sexual dysfunction researcher Irwin Goldstein MD, tells
WebMD that loss of sexual desire is a common and
underreported problem among women taking hormonal
contraceptives or hormone replacement therapy."
CONTINUE READING >
Hormone Replacement Therapy Revisited
(05/27/2004,
NBC News 10)
"Women seeking relief from the symptoms of menopause
should not rule out all forms of hormone replacement
therapy.
A new report in the journal Science says newer,
non-traditional estrogen formulations are key to the
future of HRT.
The researchers agreed that the most widely used forms
of hormone replacement-- the drugs premarin and prempro--
carry health risks that outweigh their benefits.
But the report says you cannot say those findings might
not be true to all forms of estrogen and progesterone
replacement."
Plant-Derived Estrogen Wins FDA Approval
(05/11/2004,
Reuters Health)
"By Ransdell Pierson and Jed Seltzer NEW YORK (Reuters)
- U.S. regulators have approved Barr Pharmaceuticals
Inc.'s second plant-derived female hormone replacement
tablet, an alternative to animal-derived products that
have been linked to serious health risks.
Barr spokeswoman Carol Cox said there is no proof the
company's new Enjuvia tablets are safer than estrogens
made from animal proteins such as Wyeth's Premarin,
whose sales have plunged since being linked to stroke
and blood clots.
"We can't make a claim for that. Our product gives women
another option," Cox said."
CONTINUE READING >
Ultra Low-dose Estrogen Improves Bone Density
(05/04/2004,
Reuters Health)
"PHILADELPHIA (Reuters
Health) - Among older postmenopausal women, treatment
with a skin patch delivering ultra-low doses of estrogen
significantly increases bone mineral density (BMD),
report US investigators.
At the same time, there's no
worrying increase in thickness of the endometrium, a
possible risk factor for uterine cancer.
The findings come from a
clinical trial reported here during the annual meeting
of the American College of Obstetricians and
Gynecologists."
CONTINUE READING >
WHI Study Finds No Heart Disease Benefit, Increased
Stroke Risk with Estrogen Alone
(04/13/2004,
National Heart, Lung, and Blood Institute)
"These findings
confirm that estrogen-alone therapy should not be used
to prevent chronic disease," said NHLBI Acting Director
Dr. Barbara Alving. "We believe the findings support
current FDA recommendations that hormone therapy only be
used to treat menopausal symptoms and that it be used at
the smallest effective dose for the shortest possible
time."
"The results make
clear that hormone therapy does not protect women
against coronary heart disease and increases their risk
for stroke," said Dr. Jacques Rossouw, WHI Project
Officer at NHLBI. "This may be especially true for older
women, such as those aged 60 and older in this study."
CONTINUE READING >
FDA Plans to Evaluate Results of Women's Health
Initiative Study for Estrogen-Alone Therapy
(03/02/2004, Food and Drug Administration)
"The estrogen plus
progestin trial of the WHI study was stopped in July
2002 after 5.6 years of follow-up because of an
increased risk of breast cancer. The risk of breast
cancer, heart disease, stroke, and blood clots observed
with the estrogen plus progestin combination outweighed
the benefits on hip fracture and colon cancer.
Since July 2002,
FDA has been working closely with manufacturers of
postmenopausal hormone therapies to update product
labeling so that women along with their healthcare
providers can make the best possible treatment decisions
for their individual needs. The memory substudy of the
WHI (WHIMS) was also halted in May 2003, after the data
showed an increased risk of probable dementia in women
65 or older, and that combined estrogen and progestin
therapy failed to prevent mild cognitive impairment
(memory loss)."
CONTINUE READING >
NIH Asks Participants in Women's Health Initiative
Estrogen-Alone Study to Stop Study Pills, Begin
Follow-up Phase
(03/02/2004, National Heart, Lung,
and Blood Institute)
The
increased risk of stroke in the estrogen-alone study is
similar to what was found in the WHI study of estrogen
plus progestin when that trial was stopped in July 2002.
In that study, women taking estrogen plus progestin had
8 more strokes per year for every 10,000 women than
those taking the placebo. The NIH believes that an
increased risk of stroke is not acceptable in healthy
women in a research study. This is especially true if
estrogen alone does not affect (either increase or
decrease) heart disease, as appears to be the case in
the current study.
CONTINUE READING >
HRT / PREMPRO ARTICLES
The
Women's Health Initiative (WHI) is a major 15-year
research program to address the most common causes of
death, disability and poor quality of life in
postmenopausal women -- cardiovascular disease, cancer,
and osteoporosis.
READ ARTICLE >
Hormone therapy for menopause: Who should take it and
what are the alternatives? From the Mayo Clinic staff.
READ ARTICLE >
Hormone therapy, by the American College of
Obstetricians and Gynecologists
READ ARTICLE >
Hormones after Menopause, from the National Institute on
Aging.
READ ARTICLE >
WebMD - HRT and Ovarian Cancer, The Increased Risk.
READ ARTICLE >
Menopause and Hormones, from the Food and Drug
Administration.
READ ARTICLE >
Changes in the Use of Postmenopausal Hormone Replacement
Therapy after the Publication of Study Results, from the
American College of Physicians.
READ ARTICLE >
Hormone Therapy Raises Risk of Breast Cancer Recurrence,
by the American Cancer Society
READ ARTICLE >
Menopause: An Update, 2003, from the National Institute
on Aging
READ ARTICLE >
Rates of Dementia Increase among Older Women on
Combination Hormone Therapy, from the National Institute
on Aging
READ ARTICLE >
Statement on Hormone Therapy for the Prevention and
Treatment of Postmenopausal Osteoporosis, by the
American College of Obstetricians and Gynecologists
READ ARTICLE >
Q&A
on Hormone Replacement Therapy and Breast Cancer Risk,
from the American Medical Women’s Association
READ ARTICLE >
NEWS |
ARTICLES
|
|
|
|
